Pioneering work to accelerate drug discovery earned the SGC the 2016 Oxford Academic Health Science Network (Oxford AHSN) collaboration award.
Target-enabling packages provide a crucial link between human genetics and disease biology to accelerate drug discovery in cancer and malaria
A groundbreaking partnership between the Alzheimer’s Research UK Drug Discovery Alliance (DDA) and the Structural Genomics Consortium (SGC), an international group of academic and industrial researchers with a strong track record in uncovering new drug targets and enabling new clinical trials, quickly.
An updated version of The Chemical Probes Portal is now live with new content, including a lot more data about the existing probes, reviewer ratings and their comments.
For a second year, SGC Toronto hosted a team of senior law students from the University of Toronto's Faculty of Law as part of an externship clinic to help SGC draft new agreements protecting our open access ethos and promoting our open science.
FOP patient groups have announced an extension of their support to the FOP research team in SGC Oxford led by Dr Alex Bullock since 2008. The team, currently comprising two postdoctoral fellows, is working towards developing a treatment for the rare monogenic disease Fibrodysplasia Ossificans Progressiva (FOP), a disorder that causes severely debilitating extraskeletal bone formation and impairs movement.
We are delighted to announce a groundbreaking partnership between The Brain Tumour Charity and the Structural Genomics Consortium (SGC), an international group of academic and industrial researchers with a strong track record in uncovering new drug targets and initiating clinical trials within unusually short timeframes.
An exhibition of work produced by students of the Arts University Bournemouth in collaboration with the SGC
Registration is now open for the Joint Malaria Symposium: “Science and policy shield the vulnerable from malaria”. The symposium will be held on Monday, 20 June 2016, at McGill University in Montreal, Quebec, Canada from 9am-1pm.
After 12 years, SGC’s pharma partners remain committed to the consortium because, they say, they can reproduce its work. CEO Aled Edwards reflects on the lessons he’s learned from working with industry since the consortium’s inception, and he defines eight principles that when applied in combination to a research program can increase the reliability of the program’s output.